U.S. Movers: Astera Labs, Lattice Semiconductor, Vertex Pharma

Scott Peters
11 Feb, 2025
New York City

Vertex Pharmaceuticals Inc. dropped 0.4% to $467.98 after the biotech company posted lower income in the fourth quarter ending in December.

Revenue increased to $2.91 billion from $2.52 billion, net income dropped to $913.0 million from $968.8 million, and earnings per diluted share fell to $3.50 from $3.71 a year ago.

Revenue growth was primarily driven by the continued performance of TRIKAFTA/KAFTRIO, a prescription medicine used for the treatment of cystic fibrosis.

For fiscal 2025, the company estimated revenue between $11.75 billion and $12.0 billion, compared to $11.02 billion in 2024.

Astera Labs Inc. dropped 4.5% to $98.65 despite the provider of plug-and-play data network switches for artificial intelligence servers reporting strong fourth-quarter sales and profit growth.

Revenue increased to $141.1 million from $50.5 million, net income jumped to $24.7 million from $14.3 million, and earnings per diluted share rose to 14 cents from zero cents a year ago.

For the first quarter of 2025, the company estimated revenue between $151 million and $155 million, compared to $65.3 million in the same quarter last year, and GAAP earnings per diluted share between 3 cents and 4 cents, compared to a loss of $1.77 a year ago.

Lattice Semiconductor Corp. surged 13.9% to $62.04 despite the maker of low-power field-programmable gate arrays reporting weak fourth-quarter results.

Revenue declined to 31.2% to $117.4 million from $170.6 million, net income slumped 83.3% to $16.5 million from $98.7 million, and earnings per diluted share dropped to 12 cents from 71 cents a year ago.

For the first quarter of 2025, the company estimated revenue between $115 million and $125 million, and earnings per share between 20 cents and 24 cents.

The company’s board authorized the repurchase of an additional $100 million of its outstanding common stock through the end of December 2025.

The company has repurchased approximately 6 million shares since the fourth quarter of 2020, thereby reducing dilution by 4.3%.